Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients
    Meeting Abstract

    Pusztai, L.; Lu, H.; Hale, C.; Grosse-Wilde, A.; Specht, J.; Modi, S.; Han, H.; Cortes, J.; Oliveira, M.; Garfin, P.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 1 study of AMG 160, a half-life extended BiTE(R) (Bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Dorff, T.; Rettig, M.; Machiels, J. P.; Lolkema, M.; Autio, K.; Greil, R.; Rottey, S.; Adra, N.; Salvati, M.; Poon, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples
    Meeting Abstract

    Hether, T.; Howes, T.; Spencer, C.; Hollman, T.; Reeves, J.; Wells, D.; Friedman, C.; LaVallee, T.; Wolchok, J.; Warren, S.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells
    Meeting Abstract

    Draganov, D.; Santidrian, A.; Minev, I.; Nguyen, D.; Zamarin, D.; Marincola, F.; Minev, B.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: A phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody
    Meeting Abstract

    Farwell, M.; Gamache, R.; Pandit-Taskar, N.; Postow, M.; Gordon, M.; Wilson, I.; Mascioni, A.; Wu, A.; Le, W.; Weiss, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
    Meeting Abstract

    Zappasodi, R.; Serganova, I.; Cohen, I.; Maeda, M.; Senbabaoglu, Y.; Shindo, M.; Maniyar, R.; Mane, M.; Leftin, A.; Watson, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase IB/II open-label, randomized evaluation of atezolizumab (atezo) plus selicrelumab (seli) plus gemcitabine plus nab-paclitaxel (gem plus nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
    Meeting Abstract

    Manji, G.; Bahary, N.; Chung, V.; Dalenc, F.; Ducreux, M.; Gomez-Roca, C.; Im, S. A.; Kortmansky, J.; Lacy, J.; Segal, N.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Dynamic monitoring of response to immune checkpoint blockade through deep-learning empowered ultra-sensitive liquid biopsy in melanoma
    Meeting Abstract

    Widman, A.; Khamnei, C.; Bass, J.; Liao, W.; Shah, M.; Robine, N.; Wolchok, J.; Callahan, M.; Landau, D.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer
    Meeting Abstract

    Bortone, D.; Vensko, S.; Entwistle, S.; Cogdill, A.; Monette, A.; Najjar, Y.; Sweis, R.; Tschernia, N.; Wennerberg, E.; Bommareddy, P.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Genomics of multiple myeloma influences the expression of CAR T-cell targets
    Meeting Abstract

    Yu, C.; Walker, B.; Roodman, G. D.; Huang, K.; Sadelain, M.; Perna, F.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save